References
- Akkarathamrongsin S, Thong VD, Payungporn S, et al (2014). IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol, 86, 1482-90. https://doi.org/10.1002/jmv.23957
- Bibert S, Roger T, Calandra T, et al (2013). IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med, 210, 1109-16. https://doi.org/10.1084/jem.20130012
- Castera L, Pinzani M, Bosch J (2012). Non invasive evaluation of portal hypertension using transient elastography. J Hepatol, 56, 696-703. https://doi.org/10.1016/j.jhep.2011.07.005
- Cheng L, Sun X, Tan S, et al (2014). Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res, 44, 1000-7. https://doi.org/10.1111/hepr.12284
- de Niet A, Takkenberg RB, Benayed R, et al (2012). Genetic variation in IL28B and treatment outcome in HBeAgpositive and-negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir. Scand J Gastroenterol, 47, 475-81. https://doi.org/10.3109/00365521.2011.648952
- Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52. https://doi.org/10.7314/APJCP.2012.13.3.743
- Ge D, Fellay J, Thompson AJ, et al (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461, 399-401. https://doi.org/10.1038/nature08309
- Holmes JA, Nguyen T, Ratnam D, et al (2013). IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferonalpha. J Gastroenterol Hepatol, 28, 861-6. https://doi.org/10.1111/jgh.12110
- Hoofnagle JH, Doo E, Liang TJ, et al (2007). Management of hepatitis B: summary of a clinical research workshop. Hepatology, 45, 1056-75. https://doi.org/10.1002/hep.21627
- Lampertico P, Vigano M, Cheroni C, et al (2013). IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigennegative patients with chronic hepatitis B. Hepatology, 57, 890-6. https://doi.org/10.1002/hep.25749
- Prokunina-Olsson L, Muchmore B, Tang W, et al (2013). A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet, 45, 164-71. https://doi.org/10.1038/ng.2521
- Rauch A, Kutalik Z, Descombes P, et al (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138, 1338-45. https://doi.org/10.1053/j.gastro.2009.12.056
- Sonneveld MJ, Wong VW, Woltman AM, et al (2012). Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology, 142, 513-20. https://doi.org/10.1053/j.gastro.2011.11.025
- Stattermayer AF, Scherzer T, Beinhardt S, et al (2014). Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther, 39, 1059-70. https://doi.org/10.1111/apt.12717
- Sung JJ, Tsoi KK, Wong VW, et al (2008). Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther, 28, 1067-77. https://doi.org/10.1111/j.1365-2036.2008.03816.x
- Suppiah V, Moldovan M, Ahlenstiel G, et al (2009). IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet, 41, 1100-4. https://doi.org/10.1038/ng.447
- Tanaka Y, Nishida N, Sugiyama M, et al (2009). Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 41, 1105-9. https://doi.org/10.1038/ng.449
- Tangkijvanich P, Komolmit P, Mahachai V, et al (2010). Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res, 40, 269-77. https://doi.org/10.1111/j.1872-034X.2009.00592.x
- Terczynska-Dyla E, Bibert S, Duong FH, et al (2014). Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun, 5, 5699. https://doi.org/10.1038/ncomms6699
- Thomas DL, Thio CL, Martin MP, et al (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461, 798-801. https://doi.org/10.1038/nature08463
- Tseng TC, Yu ML, Liu CJ, et al (2011). Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther, 16, 629-37. https://doi.org/10.3851/IMP1841
- Wu H, Zhao G, Qian F, et al (2015). Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. Liver Int, 35, 473-81. https://doi.org/10.1111/liv.12491
- Zhang Q, Lapalus M, Asselah T, et al (2014). IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat, 21, 525-32. https://doi.org/10.1111/jvh.12177
Cited by
- rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients pp.14783223, 2018, https://doi.org/10.1111/liv.13526